-
May 23, 2013
Irish drugmaker Elan has once again spurned the advances on Royalty Pharma, despite the latter having upped its bid to $12.50 a share, or around $6.4 billion.
Full story
-
April 16, 2013
Royalty Pharma has raised its offer to buy Elan Corp, in a move that values the Irish drugmaker to up to $7.30 billion
Full story
-
April 04, 2013
Elan Corp has welcomed a decision by the Irish Takeover Panel which states that investment group Royalty Pharma needs to make a concrete offer for the Dublin-based group by May 10 or walk away
Full story
-
March 07, 2013
Elan Corp is still not impressed by Royalty Pharma's $6.50 billion takeover bid as the private fund stepped up its efforts to persuade the Irish drugmaker's shareholders to accept the offer
Full story
-
May 28, 2012
Shares in Amylin Pharmaceuticals leapt over 8% after a report from Bloomberg claimed that Sanofi and Merck & Co have made initial takeover bids for the diabetes specialist
Full story
-
May 10, 2012
GlaxoSmithKline is taking the hostile route in its $2.60 billion bid to buy Human Genome Sciences, going straight to shareholders with its previously-rejected offer instead of participating in the latter's "strategic alternatives review"
Full story
-
April 20, 2012
In confirming its unsolicited $2.60 billion bid for Human Genome Sciences, which has been rejected, GlaxoSmithKline says it still hopes to push through the deal "on a friendly basis"
Full story
-
April 19, 2012
Human Genome Sciences has turned down an unsolicited proposal from GlaxoSmithKline, its partner for the lupus drug Benlysta to acquire the firm for $13.00 per share in cash
Full story
-
April 19, 2012
Roche looks set to walk away from its proposed hostile takeover of Illumina after deciding not to extend its $51.00 per share offer and suffering a knockback from the US gene specialist's shareholders
Full story
-
April 11, 2012
Another proxy advisory firm has given its support to the board at Illumina in its long-running battle to prevent Roche taking control of the US gene sequencing specialist
Full story